Desert Daily

Constipation Pipeline Insights, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

 Breaking News
  • No posts were found

Constipation Pipeline Insights, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

September 19
00:50 2023
Constipation Pipeline Insights, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)

DelveInsight’s, “Constipation Pipeline Insight 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Constipation pipeline landscape. It covers the Constipation pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Constipation pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Constipation Pipeline Report

  • DelveInsight’s Constipation pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Constipation treatment.
  • The leading companies working in the Constipation Market include Anji Pharma, Yuhan, Theravance Biopharma, RaQualia Pharma, Processa Pharmaceuticals, Abbott, AbbVie`s Inc., Albireo Pharma, Inc., AstraZeneca, Bausch Health Companies Inc., Bayer AG, Cosmo Pharma, and others.
  • Promising Constipation Pipeline Therapies in the various stages of development include Linaclotide, Pradigastat Tablets 20mg, Methylnaltrexone, N-methylnaltrexone bromide (MOA-728), Prucalopride, and others.
  • On June 2023, Takeda announced a study of Phase 3 Clinical Trials for Prucalopride. Participants will visit the clinic a few times during treatment. The clinic staff will also telephone the participants, or their parents or caregivers throughout treatment for a check-up 4 weeks after last treatment, the clinic staff will telephone the participants, or their parents or caregivers for a final check-up.
  • On September 2023, AbbVie announced a study of Phase 2 Clinical Trials for Linaclotide. Participants will receive oral solution of linaclotide prepared from capsule by parent/guardian once daily for 4 weeks.

 

Request a sample and discover the recent advances in Constipation Treatment Drugs @ Constipation Pipeline Report

 

The Constipation pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Constipation drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Constipation clinical trial landscape.

 

Constipation Overview

Constipation is a condition in which you may have fewer than three bowel movements a week; stools that are hard, dry, or lumpy; stools that are difficult or painful to pass; or a feeling that not all stool has passed. In many patients, constipation is associated with sluggish movement of stool through the colon.

 

Find out more about Constipation Treatment Drugs @ Drugs for Constipation Treatment

 

Constipation Emerging Drugs Profile

  • Pradigastat : Anji Pharma
  • YH 12852 : Yuhan
  • RQ 00000010 : RaQualia Pharma
  • RQ 00433412 : RaQualia Pharma

 

Constipation Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Constipation. The Constipation companies which have their Constipation drug candidates in the most advanced stage, i.e. phase II include, Anji Pharma.

 

Learn more about the emerging Constipation Pipeline Therapies @ Constipation Clinical Trials Assessment

 

Scope of the Constipation Pipeline Report

  • Coverage- Global
  • Constipation Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Constipation Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I,Phase II, Phase III
  • Constipation Companies- Anji Pharma, Yuhan, Theravance Biopharma, RaQualia Pharma, Processa Pharmaceuticals, Abbott, AbbVie`s Inc., Albireo Pharma, Inc., AstraZeneca, Bausch Health Companies Inc., Bayer AG, Cosmo Pharma, and others.
  • Constipation Pipeline Therapies- Linaclotide, Pradigastat Tablets 20mg, Methylnaltrexone, N-methylnaltrexone bromide (MOA-728), Prucalopride, and others.

 

Dive deep into rich insights for new drugs for Constipation Treatment, Visit @ Constipation Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Constipation: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Constipation– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Pradigastat : Anji Pharma
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. RQ 00000010: RaQualia Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. RQ 00433412 : RaQualia Pharma
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Constipation Key Companies
  21. Constipation Key Products
  22. Constipation – Unmet Needs
  23. Constipation – Market Drivers and Barriers
  24. Constipation – Future Perspectives and Conclusion
  25. Constipation Analyst Views
  26. Constipation Key Companies
  27. Appendix

 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking